Mirror Biologics, Inc., a clinical stage biopharmaceutical company today announced the appointment of industry veteran Scott Filosi as Chief Executive.
Luzsana to co-develop medicines with parent company Hengrui Pharma and commercialize in North America, Europe and Japan Initial pipeline focuses on 11.